CYP51A1 and parasitic infectious disease: In comparison, the use of voriconazole (second-generation triazole antimycotic) achieved 80% reduction [23], and VNI (sterol 14α-demethylase (CYP51) inhibitor) and its derivative VFV achieved reductions in parasitemia of 99.7% and 91% to 100%, respectively [24].